Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of Monoclonal Antibody Therapies
7/24/2013 9:47:15 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROTTERDAM, the Netherlands & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize its technologies. The round was led by Atlas Venture. With the funding, pharma executive BJ Bormann, Ph.D. has been named as CEO. Bormann’s previous positions have included SVP of Business Development and Licensing at Boehringer Ingelheim and VP of Strategic Alliances at Pfizer. Atlas Venture’s Peter Barrett will join the Board of Directors as Chairman.
Help employers find you! Check out all the jobs and post your resume.